|
As a leading expert in neurodegenerative disorders such as Huntington's disease (HD), Dr. Hersch brings a wealth of experience to the Avicena Group's clinical research programs. As lead investigator, Dr. Hersch recently completed a Phase II clinical trial evaluating the Avicena Group's drug candidate for treating HD.
An active and highly-regarded clinician, Dr. Hersch has served as an investigator on a number of clinical trials in the neurodegenerative disease area. In recent years, he has worked on understanding the role of huntingtin protein in the pathogenesis of HD and examined the role of transcriptional dysfunction in HD pathogenesis and therapeutics. His research involving the use of transgenic mice to examine mechanisms of disease has resulted in many compounds being advanced to clinical trials. At the same time, Dr. Hersch has performed clinical research on HD, including therapeutic trials and biomarker research.
Dr. Hersch also contributes to the drug discovery program at the MassGeneral Institute for Neurodegenerative Disease (MIND) by overseeing the testing of potential therapeutic compounds in transgenic mice models of HD and translating novel therapeutics to early phase clinical trials. In addition, Dr. Hersch directs clinical care for HD patients provided by the New England Center of Excellence for Huntington's Disease and sees patients in the movement disorders unit at MGH.
Dr. Hersch received M.D. and Ph.D. degrees from Boston University. He completed his medical internship, neurology residency and post-doctoral fellowship in neurobehavior at Emory University. Dr. Hersch is also a board certified neurologist. | 